Cost-effectiveness of sacral neuromodulation compared to botulinum neurotoxin a or continued medical management in refractory overactive bladder

Value in Health

Volumn 14, Issue 2, 2011, Pages 219-228

  Arlandis, Salvador ^a   Castro, David ^b   Errando, Carlos ^c   Fernández, Eldiberto ^d   Jiménez, Miguel ^d   González, Paloma ^e   Crespo, Carlos ^f,g   Staeuble, Funke ^h   Rodríguez, José Manuel ^e   Brosa, Max ^f  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Hospital Clínico   (Spain)

^c FUNDACIÓ PUIGVERT   (Spain)

^d HOSPITAL RAMÓN Y CAJAL   (Spain)

^e SA   (Spain)

^f Oblikue Consulting   (Spain)

^g UNIVERSITY OF BARCELONA   (Spain)

^h Medtronic International Trading Sarl   (Switzerland)

Author keywords

Budget impact; Cost effectiveness; QALY; Refractory overactive bladder; Sacral neuromodulation

Indexed keywords

BOTULINUM TOXIN A;

ARTICLE; BLADDER RECONSTRUCTION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE INCREASE; FOLLOW UP; HEALTH CARE COST; HUMAN; IDIOPATHIC DISEASE; MAJOR CLINICAL STUDY; MONTE CARLO METHOD; MULTIPLE CYCLE TREATMENT; NEUROMODULATION; OUTCOMES RESEARCH; OVERACTIVE BLADDER; PATIENT REFERRAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REPEATED DRUG DOSE; SACRAL SPINAL CORD; SPAIN; TREATMENT FAILURE; TREATMENT OUTCOME; TREATMENT RESPONSE; URINE INCONTINENCE;

EID: 79959575869     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2010.08.006     Document Type: Article

References (36)

1. Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: Report from the standardisation sub-committee of the International Continence Society. Urology 2003;61:37-49. (Pubitemid 36151708)
2. Coyne KS, Payne C, Bhattacharyya SK, et al. The impact of urinary urgency and frequency on health-related quality of life in overactive bladder: Results from a national community survey. Value Health 2004;7:455-63. (Pubitemid 39038454)
3. Martínez Agulló E, Ruiz Cerdá JL, Gómez Pérez L, et al. Grupo de Estudio Cooperativo EPICC. Prevalencia de incontinencia urinaria y vejiga hiperactiva en la población española: Resultados del estudio EPICC [Prevalence of urinary incontinence and hyperactive bladder in the Spanish population: Results of the EPICC study]. Actas Urol Esp 2009; 33:159-66.
4. Reeves P, Irwin D, Kelleher C, et al. The current and future burden and cost of overactive bladder in five European countries. Eur Urol 2006;50:1050-7. (Pubitemid 44486484)
5. Abrams P, Anderson KE, Brubaker L, et al. Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abram P, Cardozo L, Khoury S, Wein A, eds. 3rd International Consultation on Incontinence. Plymouth: Health Publications 2005.
6. Wein AJ. Diagnosis and treatment of the overactive bladder. Urology 2003;62(5 Suppl. 2):20-7. (Pubitemid 37510014)
7. Campbell UB, Stang P, Barron R. Survey assessment of continuation of and satisfaction with pharmacological treatment for urinary incontinence. Value Health 2007;17: 726-32. (Pubitemid 352032811)
8. D'Souza AO, Smith MJ, Miller LA, et al. Persistence, adherence, and switch rates among extended-release and immediate-release overactive bladder medications in a regional managed care plan. J Manag Care Pharm 2008;14: 291-301. (Pubitemid 351711980)
9. Brazzelli M, Murray A, Fraser C. Efficacy and safety of sacral nerve stimulation for urinary urge incontinence: A systematic review. J Urol 2006;175:835-41. (Pubitemid 43199992)
10. Schmidt RA, Jonas U, Oleson KA, et al. Sacral nerve stimulation for treatment of refractory urinary urge incontinence. Sacral Nerve Stimulation Study Group. J Urol 1999;162:352-7 (Pubitemid 29434339)
11. van Kerrebroeck PE, van Voskuilen AC, Heesakkers JP, et al. Results of sacral neuromodulation therapy for urinary voiding dysfunction: Outcomes of a prospective, worldwide clinical study. J Urol 2007;178:2029-34. (Pubitemid 47554439)
12. Siegel SW, Catanzaro F, Dijkema HE, et al. Long-term results of a multicenter study on sacral nerve stimulation for treatment of urinary urge incontinence, urgency-frequency, and retention. Urology 2000;56:87
13. Schmid DM, Sauermann P, Werner M, et al. Experience with 100 cases treated with botulinum-A toxin injections in the detrusor muscle for idiopathic overactive bladder syndrome refractory to anticholinergics. J Urol 2006;176:177-85. (Pubitemid 43815416)
14. Menn P, Holle R. Comparing Three Software Tools for Implementing Markov Models for Health Economic Evaluations. Pharmacoeconomics 2009;27:745-53.
15. Abrams P, Anderson KE, et al. Recommendations of the International Scientific Committee: Evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abram P, Cardozo L, Khoury S, Wein A, eds. 3rd International Consultation on Incontinence. Plymouth: Health Publications, 2005.
16. Thüroff J, Abrams P, Andersson K, Artibani W, Chartier- Kastler E, Hampel C, Van Kerrebroeck P. Guidelines on urinary incontinence. G. Aus (Ed.) European Association of Urology (EAU) guidelines (European Association of Urology, Arnhem, the Netherlands, 2008) 3-7. Available from: Http://www.uroweb.org/fileadmin/user-upload/Guidelines/ 16%20Urinary%20Incontinence.pdf [Accessed January 25, 2011].
17. Drummond M. Cost-effectiveness guidelines for reimbursement of pharmaceuticals: Is economic evaluation ready for its enhanced status? Health Economics 2006;2:85-92.
18. Van Voskuilen AC, Oerlemans DJ, Weil EH, et al. Mediumterm experience of sacral neuromodulation by tined lead implantation. BJU Int 2007;99:107-10. (Pubitemid 44915629)
19. Kessler TM, Madersbacher H, Kiss G. Prolonged sacral neuromodulation testing using permanent leads: A more reliable patient selection method? Eur Urol 2005;47:660-5. (Pubitemid 40521916)
20. Kuo HC. Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity. J Urol 2007;178: 1359-63.
21. Del Popolo G, Filocamo MT, Li Marzi V. Neurogenic detrusor overactivity treated with English botulinum toxin: 8-year experience of one single centre. Eur Urol 2008;53:1013-20. (Pubitemid 351434489)
22. Esnaola S, Martín U, Pérez Y, et al. Magnitud y desigualdades en la esperanza de vida ajustada por calidad en la Comunidad Autónoma del País Vasco. Health Department. Vasque Gobierno Vasco. 2007. Available from: Http://www.osanet.euskadi.net/r85-13714/es/contenidos/ informacion/estado-salud/es-5463/adjuntos/informe% 20EVAC%2020061212.pdf [Accessed June 3, 2009].
23. Wu JM, Siddiqui NY, Amundsen CL, et al. Cost-effectiveness of botulinum toxin a versus anticholinergic medications for idiopathic urge incontinence. J Urol 2009;181:2181-6.
24. Ortega JA. Estudio de concordancia entre el diagnóstico clínico de incontinencia de orina en la mujer realizado en una Unidad de Suelo Pelviano de un programa de atención a la mujer en Atención Primaria. PhD Thesis 2003. Available from: Http://www.tesisenxarxa.net/TESIS-UB/ AVAILABLE/ TDX-0326104-083750//TESISORTEGA.pdf [Accessed June 3, 2009].
25. Khan S, Kessler TM, Apostolidis A, et al. What a patient with refractory idiopathic detrusor overactivity should know about botulinum neurotoxin type a injection. J Urology 2009; 181:1773-8.
26. Sacristan JA, Oliva J, Del Llano J, et al. What is an efficient health technology in Spain? [in Spanish]. Gac Sanit 2002;16: 334-43.
27. Deutekom M, Terra MP, Dobben AC, et al. Impact of faecal incontinence severity on health domains. Colorectal Dis 2005;7:263-9. (Pubitemid 40637427)
28. Mihaylova B, Pitman R, Tincello D, et al. Cost-effectiveness of duloxetine: The Stress Urinary Incontinence Treatment (SUIT) study. Value Health 2010;13:565-72. Epub 2010 Apr 23
29. Siddiqui NY, Amundsen CL, Visco AG, et al Costeffectiveness of sacral neuromodulation versus intravesical botulinum a toxin for treatment of refractory urge incontinence. J Urol 2009;182;2799-804.
30. Watanabe JH, Campbell JD, Ravelo A, et al. Treatment success for overactive bladder with urinary urge incontinence refractory to oral antimuscarinics: A review of published evidence. BMC Urol 2009;9:18.
31. Schmid DM, Roy S, Sulser T, Scheiner D. Prospects and limitations of treatment with botulinum neurotoxin type A for patients with refractory idiopathic detrusor overactivity. BJU Int 2008;25(Suppl 1):7-10.
32. Spinelli M, Giardiello G, Arduini A, van den Hombergh U. New percutaneous technique of sacral nerve stimulation has high initial success rate: Preliminary results. Eur Urol 2003;43:70-4. (Pubitemid 36134319)
33. Bosch JL, Kelleher C, van Kerrebroeck PE, Schurch B. What treatment should we use if drugs fail for OAB; and, what really works after drugs? Neurourol Urodyn 2010;29:658-61.
34. Jimenez Cidre MA. [Urinary incontinence: Anticholinergic treatment] (Spanish). Rev Med Univ Navarra 2004;48:37-42.
35. Sculpher M, Claxton K. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty-when is there sufficient evidence? Value Health 2005;8:433-46.
36. López-Bastida J, Oliva J, Antoñanzas F, et al. Spanish recommendations on economic evaluation of health technologies. Eur J Health Econ 2010;11:513-20. Epub 2010 Apr 20.